Systemic Sclerosis

You have full text access to this OnlineOpen article

Validation of potential classification criteria for systemic sclerosis

  1. Sindhu R. Johnson1,*,
  2. Jaap Fransen2,
  3. Dinesh Khanna3,
  4. Murray Baron4,
  5. Frank van den Hoogen5,
  6. Thomas A. Medsger Jr.6,
  7. Christine A. Peschken7,
  8. Patricia E. Carreira8,
  9. Gabriela Riemekasten9,
  10. Alan Tyndall10,†,
  11. Marco Matucci-Cerinic11,‡,
  12. Janet E. Pope12

Article first published online: 28 FEB 2012

DOI: 10.1002/acr.20684

Issue

Arthritis Care & Research

Arthritis Care & Research

Volume 64, Issue 3, pages 358–367, March 2012

Additional Information

How to Cite

Johnson, S. R., Fransen, J., Khanna, D., Baron, M., van den Hoogen, F., Medsger, T. A., Peschken, C. A., Carreira, P. E., Riemekasten, G., Tyndall, A., Matucci-Cerinic, M. and Pope, J. E. (2012), Validation of potential classification criteria for systemic sclerosis. Arthritis Care Res, 64: 358–367. doi: 10.1002/acr.20684

Author Information

  1. 1

    Toronto Western Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, Ontario, Canada

  2. 2

    Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

  3. 3

    University of Michigan Scleroderma Program, Ann Arbor

  4. 4

    Jewish General Hospital, McGill University, Montreal, Quebec, Canada

  5. 5

    Sint Maartenskliniek, Nijmegen, The Netherlands

  6. 6

    University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

  7. 7

    University of Manitoba, Winnipeg, Manitoba, Canada

  8. 8

    Hospital Universitario 12 de Octubre, Madrid, Spain

  9. 9

    German Rheumatology Research Center, Leibniz Institute, Berlin, Germany

  10. 10

    University of Basel, Basel, Switzerland

  11. 11

    University of Florence, Florence, Italy

  12. 12

    St. Joseph's Health Care, University of Western Ontario, London, Ontario, Canada

  1. †

    Dr. Tyndall has served on the advisory boards for Novartis, Actelion, Roche, and MSD and received a fee (less than $10,000 each).

  2. ‡

    Dr. Matucci-Cerinic has received consultant fees, speaking fees, and/or honoraria (less than $10,000) from Actelion, Pfizer, GSK, AstraZeneca, and BMS.

*Division of Rheumatology, Ground Floor, East Wing, Toronto Western Hospital, 399 Bathurst Street, Toronto, Ontario, Canada, M5T 2S8

  1. †

    Dr. Tyndall has served on the advisory boards for Novartis, Actelion, Roche, and MSD and received a fee (less than $10,000 each).

  2. ‡

    Dr. Matucci-Cerinic has received consultant fees, speaking fees, and/or honoraria (less than $10,000) from Actelion, Pfizer, GSK, AstraZeneca, and BMS.

Publication History

  1. Issue published online: 28 FEB 2012
  2. Article first published online: 28 FEB 2012
  3. Accepted manuscript online: 2 NOV 2011 08:55AM EST
  4. Manuscript Accepted: 14 OCT 2011
  5. Manuscript Received: 11 JUL 2011

Funded by

  • American College of Rheumatology
  • European League Against Rheumatism
  • Canadian Institutes of Health Research Clinician Scientist Award
  • Norton-Evans Fund for Scleroderma Research
  • Scleroderma Foundation (New Investigator Award)
  • NIH award (National Institute of Arthritis and Musculoskeletal and Skin Diseases). Grant Number: K23-AR053858-05

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (118K)

REFERENCES

  • 1
    Masi AT, Medsger TA Jr, Rodnan GP, Fries JF, Altman RD, Brown BW, et al. Methods and preliminary results of the Scleroderma Criteria Cooperative Study of the American Rheumatism Association. Clin Rheum Dis 1979; 5: 27–79.
  • 2
    Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581–90.
    Direct Link:
  • 3
    Preliminary criteria for the classification of systemic sclerosis (scleroderma). Bull Rheum Dis 1981; 31: 1–6.
  • 4
    Nadashkevich O, Davis P, Fritzler MJ. A proposal of criteria for the classification of systemic sclerosis. Med Sci Monit 2004; 10: CR615–21.
  • 5
    Walker JG, Pope J, Baron M, Leclercq S, Hudson M, Taillefer S, et al. The development of systemic sclerosis classification criteria. Clin Rheumatol 2007; 26: 1401–9.
  • 6
    Hudson M, Taillefer S, Steele R, Dunne J, Johnson SR, Jones N, et al. Improving the sensitivity of the American College of Rheumatology classification criteria for systemic sclerosis. Clin Exp Rheumatol 2007; 25: 754–7.
  • 7
    Johnson SR, Feldman BM, Hawker GA. Classification criteria for systemic sclerosis subsets. J Rheumatol 2007; 34: 1855–63.
  • 8
    Lonzetti LS, Joyal F, Raynauld JP, Roussin A, Goulet JR, Rich E, et al. Updating the American College of Rheumatology preliminary classification criteria for systemic sclerosis: addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for limited scleroderma [letter]. Arthritis Rheum 2001; 44: 735–6.
    Direct Link:
  • 9
    Hachulla E, Launay D. Diagnosis and classification of systemic sclerosis. Clin Rev Allergy Immunol 2011; 40: 78–83.
  • 10
    Avouac J, Fransen J, Walker UA, Riccieri V, Smith V, Muller C, et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi consensus study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis 2011; 70: 476–81.
  • 11
    Winterbauer RH. Multiple telangiectasia, Raynaud's phenomenon, sclerodactyly, and subcutaneous calcinosis: a syndrome mimicking hereditary hemorrhagic telangiectasia. Bull Johns Hopkins Hosp 1964; 114: 361–83.
  • 12
    Nadashkevich O, Davis P, Fritzler MJ. Revising the classification criteria for systemic sclerosis [letter]. Arthritis Rheum 2006; 55: 992–3.
    Direct Link:
  • 13
    Goetz R, Berne M. The pathophysiology of progressive systemic sclerosis (generalised scleroderma) with special reference to changes in the viscere. Clin Proc 1945; 4: 337–92.
  • 14
    Wollheim FA. Classification of systemic sclerosis: visions and reality. Rheumatology (Oxford) 2005; 44: 1212–6.
  • 15
    Maricq HR, Valter I. A working classification of scleroderma spectrum disorders: a proposal and the results of testing on a sample of patients. Clin Exp Rheumatol 2004; 22 Suppl: S5–13.
  • 16
    LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202–5.
  • 17
    Tuffanelli DL, Winkelmann RK. Diffuse systemic scleroderma: a comparison with acrosclerosis. Ann Intern Med 1962; 57: 198–203.
  • 18
    Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002; 81: 139–53.
  • 19
    Felson DT, Anderson JJ. Methodological and statistical approaches to criteria development in rheumatic diseases. Baillieres Clin Rheumatol 1995; 9: 253–66.
  • 20
    Classification and Response Criteria Subcommittee of the American College of Rheumatology Committee on Quality Measures. Development of classification and response criteria for rheumatic diseases [editorial]. Arthritis Rheum 2006; 55: 348–52.
    Direct Link:
  • 21
    Johnson SR, Goek ON, Singh-Grewal D, Vlad SC, Feldman BM, Felson DT, et al. Classification criteria in rheumatic diseases: a review of methodologic properties. Arthritis Rheum 2007; 57: 1119–33.
    Direct Link:
  • 22
    Dougados M, Betteridge N, Burmester GR, Euller-Ziegler L, Guillemin F, Hirvonen J, et al. EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis 2004; 63: 1172–6.
  • 23
    Dougados M, Gossec L. Classification criteria for rheumatic diseases: why and how? [editorial]. Arthritis Rheum 2007; 57: 1112–5.
    Direct Link:
  • 24
    Fransen J, Johnson SR, van den Hoogen F, Baron M, Allanore Y, Carreira PE, et al. Items for developing revised classification criteria in systemic sclerosis: results of a consensus exercise. Arthritis Care Res (Hoboken) 2012; 64: 351–7.
    Direct Link:
  • 25
    Johnson SR, Hawker GA, Davis AM. The Health Assessment Questionnaire disability index and Scleroderma Health Assessment Questionnaire in scleroderma trials: an evaluation of their measurement properties. Arthritis Rheum 2005; 53: 256–62.
    Direct Link:
  • 26
    Streiner DL, Norman GR. Health measurement scales: a practical guide to their development and use. 4th ed. Oxford: Oxford University Press; 2008.
  • 27
    Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 2004; 159: 882–90.
  • 28
    Fletcher RH, Fletcher SW. Clinical epidemiology: the essentials. 4th ed. Baltimore: Lippincott Williams and Wilkins; 2005.
  • 29
    Spiegelhalter D, Abrams K, Myles J. Bayesian approaches to clinical trials and health-care evaluation. Chichester: John Wiley & Sons; 2004.
  • 30
    Low AH, Johnson SR, Lee P. Ethnic influence on disease manifestations and autoantibodies in Chinese-descent patients with systemic sclerosis. J Rheumatol 2009; 36: 787–93.
  • 31
    Kuwana M, Kaburaki J, Arnett FC, Howard RF, Medsger TA Jr, Wright TM. Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti–DNA topoisomerase I antibody. Arthritis Rheum 1999; 42: 465–74.
    Direct Link:
  • 32
    Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66: 940–4.
  • 33
    Peschken CA, Katz SJ, Silverman E, Pope JE, Fortin PR, Pineau C, et al. The 1000 Canadian faces of lupus: determinants of disease outcome in a large multiethnic cohort. J Rheumatol 2009; 36: 1200–8.
  • 34
    Punglia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med 2003; 349: 335–42.
  • 35
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–7.
    Direct Link:
  • 36
    Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
    Direct Link:
  • 37
    Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569–81.
    Direct Link:
  • 38
    Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344–7.
  • 39
    Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292: 403–7.
View Full Article (HTML) Get PDF (118K)